ATI-2307 Exhibits Equivalent Antifungal Activity in Cryptococcus neoformans Clinical Isolates With High and Low Fluconazole IC50
| Autor: | Kirsten Nielsen, Tony S. Luggya, Sophie Altamirano, J. Marina Yoder, Andrew Akampurira, Elliot S. Gerlach, David B. Meya, David R. Boulware, Joshua Rhein |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Microbiology (medical) ATI-2307 030106 microbiology Immunology Cryptococcus Antifungal drug Context (language use) Microbiology susceptibility resistance 03 medical and health sciences Minimum inhibitory concentration Amphotericin B Medicine azole chemistry.chemical_classification Cryptococcus neoformans biology business.industry biology.organism_classification QR1-502 030104 developmental biology Infectious Diseases chemistry Azole business Fluconazole antifungal medicine.drug |
| Zdroj: | Frontiers in Cellular and Infection Microbiology, Vol 11 (2021) |
| ISSN: | 2235-2988 |
| DOI: | 10.3389/fcimb.2021.695240/full |
| Popis: | Half maximal inhibitory concentrations (IC50) to the experimental drug ATI-2307 and complete inhibition (IC90) of the common clinically used antifungal drug amphotericin B were determined by microbroth dilution assay for a collection of 69 clinical isolates of Cryptococcus neoformans from Uganda that had high fluconazole IC50 values. The majority of the clinical isolates tested had fluconazole IC50 at or above 8 µg/mL, but were susceptible to both amphotericin B (IC90 ≤1 μg/mL) and ATI-2307 (IC50 ≤0.0312 µg/mL). No correlation between increased fluconazole minimum inhibitory concentration (MIC) and ATI-2307 or amphotericin B MIC was observed, suggesting that the cellular changes impacting fluconazole susceptibility did not impact the effectiveness of ATI-2307. Our results suggest that ATI-2307 is a promising new antifungal drug for use in the context of high fluconazole or other antifungal drug MICs and/or in combination drug therapy regimens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|